Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence

AIDS

Volumn 20, Issue 17, 2006, Pages 2199-2206

  McCarthy, Kerrigan M ^a   Morgan, Juliette ^b   Wannemuehler, Kathleen A ^b   Mirza, Sara A ^b   Gould, Susan M ^a   Mhlongo, Ntombi ^c   Moeng, Portia ^c   Maloba, Bonnie R ^c   Crewe Brown, Heather H ^c   Brandt, Mary E ^b   Hajjeh, Rana A ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cryptococcosis; HIV; South Africa; Surveillance

Indexed keywords

AMPHOTERICIN B; COTRIMOXAZOLE; EFAVIRENZ; FLUCONAZOLE; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LATEX;

ADOLESCENT; ADULT; AGED; AGGLUTINATION TEST; ARTICLE; CHILD; CRYPTOCOCCOSIS; CRYPTOCOCCUS; EARLY DIAGNOSIS; FEMALE; FUNGUS ISOLATION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERVIEW; LABORATORY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL HEALTH; MINING; MORTALITY; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROPREVALENCE; SOUTH AFRICA; SURVIVAL; TIME SERIES ANALYSIS; VISION;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; CRYPTOCOCCOSIS; HIV SEROPREVALENCE; HUMANS; INCIDENCE; INFANT; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; POPULATION SURVEILLANCE; RECURRENCE; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 33750593614     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280106d6a     Document Type: Article

References (42)

1. UNAIDS. Factsheet on Sub-Saharan Africa. www.unaids.org. Accessed October 2005.
2. Department of Health. Summary report: national HIV and syphilis antenatal seroprevalence survey in South Africa 1990. Pretoria, South Africa: Directorate Health Systems Research, Research Co-ordination and Epidemiology, Department of Health 1991.
3. Department of Health. Summary report: national HIV and syphilis antenatal seroprevalence survey in South Africa 2002. Pretoria, South Africa: Directorate Health Systems Research, Research Co-ordination and Epidemiology, Department of Health 2003.
4. Bradshaw D, Nannan N, Laubscher R, Groenewald P, Joubert J, Nojiliana B, et al. South African National Burden of Disease Study 2000; Estimates of provincial mortality. Cape Town: Burden of Disease Research Unit, Medical Research Council and Actuarial Society of Southern Africa. 2005.
5. Bradshaw D, Groenewald P, Laubscher R, Nannan N, Nojiliana B, Norman R, et al. Initial burden of disease estimates for South Africa, 2000. S Afr Med J 2003; 93:682-688.
6. Department of Health. Operational plan for comprehensive HIV and AIDS care, management and treatment for South Africa. Pretoria South Africa: Department of Health; November 2003.
7. Department of Health. Monitoring Review: Progress Report on the Implementation of the Comprehensive HIV and AIDS Care, Management and Treatment Programme. September 2004. Health Information, Evaluation and Research Cluster, Department of Health 2004. www.doh.gov.za. Accessed on 07 September 2006.
8. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization; 2005, Report no. WHO/HTM/TB/2005.349.
9. Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson K. Clinical presentation and risk behaviours of patients with acquired immunodeficiency syndrome in Thailand, 1994-1998: Regional variation and temporal trends. Clin Infect Dis 2001; 32:955-962.
10. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16:1031-1038.
11. Corbett EL, Churcyard GJ, Charalambos S, Samb B, Moloi V, Clayton TC, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34: 1251-1258.
12. Bogaerts J, Roubroy D, Taelman H, Kagame A, Aziz MA, Swinne D, et al. AIDS-associated cryptococcal meningitis in Rwanda (1983-1992): epidemiologic and diagnostic features. J Infect 1999; 39:32-37.
13. Heyderman RS, Gangaidzo IT, Hakim JG, Mielke J, Taziwa A, Musvaire P, et al. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis 1998; 26:284-249.
14. Moosa MYS, Coovadia YM. Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin Infect Dis 1997; 24:131-134.
15. Bergemann A, Karstaedt AS. The spectrum of meningitis in a population with high prevalence of HIV disease. QJ Med 1996; 89:499-504.
16. Statistics South Africa. Census in brief/Statistics South Africa. Pretoria: Statistics South Africa; 2003. www.statssa.gov.za. Accessed on 07 September 2006.
17. Dorrington R, Bradshaw D, Budlenders. HIV/AIDS profile of the provinces of RSA - indicators for 2002. Cape Town: Centre for Actuarial Research, Medical Research Council and Actuarial Society of Southern Africa; 2002.
18. Wertheimer AI, Santella TM, Lauver HJ. Successful public/private donation programmes: A review of the Diflucan Partnership Program in South Africa. J Int Assoc Physicians AIDS Care 2004; 3:74-79.
19. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definiton for AIDS among adolescents and adults. MMWR (Morb Mortal Wkl Rep) 1992; 41(RR-17):1-19.
20. Hajjeh RA, Conn LA, Stephone DS, Baughman W, Hamill R, Graviss E, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999; 179:449-454.
21. Friedman GD, Jeffrey Fessel W, Udaltsova NV, Hurley LB. Cryptococcosis: the 1981-2000 epidemic. Mycoses 2005; 48:122-125.
22. Dromer F, Mathoulin S, Dupont B, Laporte A. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993) French Cryptococcosis Study Group. Clin Infect Dis 1996; 23:82-90.
23. Uys RL. Aspects of the care of people with HIV/AIDS in South Africa. Public Health Nurs 2003; 20:271-280.
24. Fisher D, Lo D, Burrow J, Currie B. Cryptococccus neoformans in tropical northern Australia; predominantly variant gattii with good outcomes. Aust NZ J Med 1993; 23:678-682.
25. Likasitwattanakul S, Poneprasert B, Sirisanthana V. Cryptococcosis in HIV-infected children. Southeast Asian J Trop Med Public Health 2004; 35:935-939.
26. Gumbo T, Kadzirange G, Mielke J, Gangaidzo IT, Hakim JG. Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2002; 21:54-56.
27. Chuck S, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321:794-799.
28. Clark RA, Greer D, Atkinson W, Valainis GT, Hyslop N. Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 1990; 12:768-777.
29. Bennett JE, Kwon-Chung KJ, Howard DH. Epidemiologic differences among sterotypes of Cryptococcus neoformans. Am J Epidemiol 1997; 105:582-586.
30. Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol 2001; 39:155-168.
31. Litvintseva A, Thakur R, Reller B, Mitchell G. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa. J Infect Dis 2005; 192:888-892.
32. Karstaedt AS, Crewe-Brown HH, Dromer F. Cryptococcal meningitis caused by Cryptococcus neoformans var gattii, serotype C, in AIDS patients in Soweto, South Africa. Med Mycol 2002; 40:7-11.
33. Shelburne SA III, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81:213-227.
34. Woods ML, MacGinley R, Eisen DP, Allworth AM. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998; 12:1491-1494.
35. King MD, Perlino CA, Cinnamon J, Jernigan JA. Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy. Int J STD AIDS 2002; 13:724-726.
36. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F, French Cryptococcosis Study Group. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043-1049.
37. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme [Letter]. AIDS 2005; 19:2050-2051.
38. Chang L, Phipps W, Kennedy G, Rutherford G. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005; 20:CD004773.
39. Tuli K, Clark T, Ningsanond P, Morgan J, Laosiritawor Y, Kongsin S, et al. Primary prohpylaxis against systemic fungal infections among persons living with AIDS in Thailand: a cost-effectiveness analysis. Tenth Conference on Retrovirus and Opportunistic Infections, Boston, February 2003 [abstract # 795].
40. Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt ME, et al. The changing epidemiology of cryptococcosis: and update from population-based active surveillance in 2 large metropolitan areas. Clin Infect Dis 2003; 36:789-794.
41. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al., Multicenter AIDS Cohort Study. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257-260.
42. Dromer F, Matholin Pelissier, Fontanet A, Ronin O, Dupont B, Lortholary O; French Cryptococcosis Study Group. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 2004; 18:555-562.